Therapeutic effect of NK cells stimulated by Toxoplasma gondii excretory/secretory antigens on B16F10 melanoma in mice

doi:10.12140/j.issn.1000-7423.2019.04.013

Abstract

Abstract:

Objective To observe the therapeutic effect of natural killer (NK) cells stimulated by Toxoplasma gondii excretory/secretory antigens (TgESA) on the growth of B16F10 melanoma in mice. Methods TgESA was obtained from the culture of T. gondii tachyzoites in vitro for 12 hours. The tumor-bearing animal models were established by direct injection of melanoma B16F10 cells into the right axillary of ten mice (2 × 10⁵/mouse). Five of the melanoma-inoculated mice were intraperitoneally treated with TgESA(100 μl/mouse) 7 days after inoculation of B16F10 cells, the rest 5 mice were treated with PBS only as control. One week after the treatment, all mice were euthanized, and the NK cells were isolated from the splenocytes of two groups (named NK_B16F10 and NK_ESA). Total 30 naïve C57BL/6 mice were randomly divided into 3 groups with 10 mice each group. Each mouse was inoculated with 2 × 10⁵ B16F10 cells subcutaneously into axillary. One week after melanoma inoculation, one group of mice were passive transferred with 2 × 10⁵ of NK_B16F10 cells through tail vein injection (group of NK_B16F10). Another group of mice were transferred with the same number of NK_ESA cells (group of NK_ESA). The third group of mice were given with PBS only as control. After passive transfer, the tumor growth, mortality and survival rate in the transferred mice were observed and recorded for 35 days. Results The visible time of tumor in mice of NK_ESA group [(14.70 ± 0.95) d] was significantly longer than that in NK_B16F10 group [(12.60 ± 0.70) d] and in control group [(8.50 ± 0.85) d] (P < 0.05). The tumor size in NK_ESA group [(577.79 ± 49.70) mm²] was also significantly smaller than that in NK_B16F10 group [(686.53 ± 17.84) mm²] and in control group [(787.84 ± 19.94) mm²] at D35. The delayed appearance of tumor and smaller tumor size in group of NK_B16F10 was also significant compared to control group. Mice began to die at D24 for control group, D27 for NK_B16F10 group and D30 for NK_ESA group after tumor inoculation, and the number of mice remain alive was 3, 4 and 6 respectively at terminal time D35 with significant difference between NK_ESA group and control group.Conclusion Passive transfer of NK cells stimulated by TgESA conferred therapeutic effect on B16F10 melanoma in recipient mice.

Key words: Toxoplasma gondii, Excretory/secretory antigens, Natural killer cells, Melanoma

CLC Number:

R382.5

Yu-meng JIAO, Hui XIA, Xue-mei WANG, Zhi-yong TAO, Lin ZHU, Qiang FANG. Therapeutic effect of NK cells stimulated by Toxoplasma gondii excretory/secretory antigens on B16F10 melanoma in mice[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2019, 37(4): 444-447.

Figures/Tables 3

References 35

[1]	Kim K, Weiss LM.Toxoplasma: the next 100 years[J]. Microbes Infect, 2008, 10(9): 978-984.
[2]	Blader IJ, Koshy AA.Toxoplasma gondii development of its replicative niche: in its host cell and beyond[J]. Eukaryotic Cell, 2014, 13(8): 965-976.
[3]	Ferguson DJ.Toxoplasma gondii: 1908-2008, homage to Nicolle, Manceaux and Splendore[J]. Mem Inst Oswaldo Cruz, 2009, 104(2): 133-148.
[4]	Darani HY, Shirzad H, Mansoori F, et al. Effects of Toxoplasma gondii and Toxocara canis antigens on WEHI-164 fibrosarcoma growth in a mouse model[J]. Korean J Parasitol, 2009, 47(2): 175-177.
[5]	Pyo KH, Jung BK, Xin CF, et al. Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatment[J]. Korean J Parasitol, 2014, 52(6): 605-612.
[6]	Thomas-Tikhonenko A, Hunter CA.Infection and cancer: the common vein[J]. Cytokine Growth Factor Rev, 2003, 14(1): 67-77.
[7]	Kim JO, Jung SS, Kim SY, et al. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis[J]. J Korean Med Sci, 2007, 22(Suppl): S38-S46.
[8]	Rankin EB, Yu DN, Jiang J, et al. An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth[J]. Cancer Biol Ther, 2003, 2(6): 687-693.
[9]	张秀昌, 蔡念光, 孙黎, 等. 弓形虫诱导人白血病细胞K562凋亡的实验观察[J]. 中国寄生虫学与寄生虫病杂志, 2007, 25(3): 185-188.
[10]	武欣, 孙黎, 张力, 等. 弓形虫对4种肿瘤细胞增殖及凋亡的影响[J]. 中国寄生虫学与寄生虫病杂志, 2012, 30(2): 157-159.
[11]	葛璞, 李春莉, 冉亚林, 等. 刚地弓形虫培养上清抑制肺癌A549细胞系增殖[J]. 基础医学与临床, 2010, 30(2): 185-188.
[12]	罗强, 孙黎, 田青青, 等. 刚地弓形虫速殖子培养上清液对人胃癌细胞BGC-823增殖和凋亡的影响[J]. 中国寄生虫学与寄生虫病杂志, 2014, 32(2): 123-127.
[13]	孔璟, 高剑, 叶彬, 等. 刚地弓形虫对荷瘤小鼠肿瘤组织微血管生成的抑制作用[J]. 中国人兽共患病学报, 2011, 27(6): 522-525.
[14]	Daryani A, Hosseini AZ, Dalimi A.Immune responses against excreted/secreted antigens of Toxoplasma gondii tachyzoites in the murine model[J]. Vet Parasitol, 2003, 113(2): 123-134.
[15]	夏菁, 彭鸿娟. 刚地弓形虫毒力调节因子研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(4): 297-300.
[16]	邱竞帆, 葛可, 王勇. 刚地弓形虫蛋白质组学研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(3): 214-218.
[17]	蒲元华, 张德林. 弓形虫入侵宿主机制及免疫学研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2012, 30(6): 480-485.
[18]	Carayannopoulos LN, Yokkoyama WM.Recognition of infected cells by natural killer cells[J]. Curr Opin Immunol, 2004, 16(1): 26-33.
[19]	Abou-Bacar A, Pfaff AW, Georges S, et al. Role of NK cells and gamma interferon in transplacental passage of Toxoplasma gondii in a mouse model of primary infection[J]. Infect Immun, 2004, 72(3): 1397-1401.
[20]	Combe CL, Curiel TJ, Moretto MM, et al. NK cells help to induce CD8+ T-Cell immunity against Toxoplasma gondii in the absence of CD4+ T Cells[J]. Infect Immun, 2005, 73(8): 4913-4921.
[21]	Sacks D, Sher A.Evasion of innate immunity by parasitic protozoa[J]. Nat Immunol, 2002, 3(11): 1041-1047.
[22]	Munoz M, Liesenfeld O, Heimesaat MM.Immunology of Toxoplasma gondii[J]. Immunol Rev, 2011, 240(1): 269-285.
[23]	焦玉萌, 章黎, 葛以跃, 等. 弓形虫排泄分泌抗原对B16F10黑素瘤小鼠CD4+CD25+Foxp3+T细胞和NK 细胞的影响[J]. 中国血吸虫病防治杂志, 2011, 23(3): 301-306.
[24]	焦玉萌, 方强, 夏惠, 等. 弓形虫ESA诱导小鼠产生的CD8+T细胞对早期黑色素瘤生长的影响[J]. 中国寄生虫学与寄生虫病杂志, 2013, 31(2): 95-98.
[25]	Li YX, Sun R.Tumor immunotherapy: new aspects of natural killer cells[J]. Chin J Cancer Res, 2018, 30(2): 173-196.
[26]	Grossenbacher SK, Aguilar EG, Murphy WJ.Leveraging natural killer cells for cancer immunotherapy[J]. Immunotherapy, 2017, 9(6): 487-497.
[27]	Caligiuri MA.Human natural killer cells[J]. Blood, 2008, 112(3): 461-469.
[28]	Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer[J]. J Immunol, 2007, 178(7): 4011-4016.
[29]	Carlsten M, Malmberg KJ, Ljunggren HG.Natural killer cell-mediated lysis of freshly isolated human tumor cells[J]. Int J Cancer, 2009, 124(4): 757-762.
[30]	Pietra G, Manzini C, Vitale M, et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells[J]. Int Immunol, 2009, 21(7): 793-801.
[31]	赵平森, 钟志雄, 翁锐强. NK细胞在肿瘤过继性免疫治疗中的临床应用与研究进展[J]. 中华肿瘤防治杂志, 2016, 23(7): 471-478.
[32]	徐道俊, 段清堂, 刘馨. NK及CAR-NK细胞在肿瘤过继免疫治疗中的运用现状及研究进展[J]. 中国新药杂志, 2017, 26(15): 1806-1813.
[33]	黄朝晖, 华东, 王丰, 等. 细胞因子诱导的NK细胞过继免疫治疗恶性肿瘤的初步应用[J]. 江南大学学报(自然科学版), 2005, 4(2): 209-211.
[34]	尚艺曼, 王子兵, 马一杰, 等. 肿瘤的过继性细胞免疫疗法[J]. 国际肿瘤学杂志, 2013, 40(2): 103-106.
[35]	王小溪, 何兴, 潘卫庆. 寄生虫感染与癌症[J]. 中国热带医学, 2019, 19(4): 392-396.